Reply to thread

Message: <blockquote data-quote="imhotep" data-source="post: 31612316" data-attributes="member: 562115">True. Just one case is not sufficient to generalize. However OVT (Oncolytic Virus Therapy) is being currently trialled with different viruses. Last August the FDA approved Tudriqev, a genetically modified oncolytic viral therapy for the treatment of advanced, refractory melanoma. For pateints with  patients with advanced melanoma that has stopped responding to PD-1 blocking therapy, the prognosis is often devastating, and options have been far too limited.Tudriqev is an oncolytic viral therapy based on a modified herpes simplex virus type 1 (HSV-1) that is engineered to selectively target and destroy cancer cells. Once inside a tumor, the virus replicates and breaks cancer cells apart, while simultaneously triggering the body’s immune system to recognize and attack the cancer. When used in combination with nivolumab, an anti-PD-1 immunotherapy, Tudriqev may help restore an anti-tumor immune response in patients whose cancer had previously stopped responding to immunotherapy.This is another variant of T-Vec (Imlygic) which was approved in 2015.Cancer cells often have impaired antiviral defenses. So engineered natural viruses have the ability to make the cancer cells to burst and release the antigens. This results in stimulating the immune system to destroy the rest of the cancer cells.So do not underestimate the potential.</blockquote>

Top Bottom